BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. 2022

Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, Jinan University, 510632, Guangzhou, P. R. China.

Sustained expression of programmed cell death receptor-1 (PD-1) is correlated with the exhaustion of T cells, and blockade of the PD-1 pathway is an effective immunotherapeutic strategy for treating various cancers. However, response rates are limited, and many patients do not achieve durable responses. Thus, it is important to seek additional strategies that can improve anticancer immunity. Here, we report that the bromodomain and extraterminal domain (BET) inhibitor JQ1 inhibits PD-1 expression in Jurkat T cells, primary T cells, and T-cell exhaustion models. Furthermore, JQ1 dramatically impaired the expression of PD-1 and T-cell immunoglobulin mucin-domain-containing-3 (Tim-3) and promoted the secretion of cytokines in T cells from patients with acute myeloid leukemia (AML). In line with that, BET inhibitor-treated CD19-CAR T and CD123-CAR T cells have enhanced anti-leukemia potency and resistant to exhaustion. Mechanistically, BRD4 binds to the NFAT2 and PDCD1 (encoding PD-1) promoters, and NFAT2 binds to the PDCD1 and HAVCR2 (encoding Tim-3) promoters. JQ1-treated T cells showed downregulated NFAT2, PD-1, and Tim-3 expression. In addition, BET inhibitor suppressed programmed death-ligand 1 (PD-L1) expression and cell growth in AML cell lines and in primary AML cells. We also demonstrated that JQ1 treatment led to inhibition of leukemia progression, reduced T-cell PD-1/Tim-3 expression, and prolonged survival in MLL-AF9 AML mouse model and Nalm6 (B-cell acute lymphoblastic leukemia cell)-bearing mouse leukemia model. Taken together, BET inhibition improved anti-leukemia immunity by regulating PD-1/PD-L1 expression, and also directly suppressed AML cells, which provides novel insights on the multiple effects of BET inhibition for cancer therapy.

UI MeSH Term Description Entries
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D000072597 Hepatitis A Virus Cellular Receptor 2 An Ig domain-containing membrane receptor that is expressed by TH1 CELLS. It regulates the activation of MACROPHAGES and inhibits TH1-mediated auto- and alloimmune responses to promote IMMUNE TOLERANCE. CD366 Antigen,HAVCR2 Protein,T-Cell Immunoglobulin Mucin Receptor 3,T-Cell Immunoglobulin and Mucin Domain-Containing Protein 3,TIMD3 Protein,Antigen, CD366,T Cell Immunoglobulin Mucin Receptor 3,T Cell Immunoglobulin and Mucin Domain Containing Protein 3
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
January 2013, PLoS pathogens,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
June 2015, Molecular cell,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
December 2016, PLoS pathogens,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
May 2017, PLoS pathogens,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
July 2019, ImmunoHorizons,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
December 2012, Biochemical and biophysical research communications,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
October 2013, The Journal of experimental medicine,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
July 2018, BMC cancer,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
December 2020, Bone marrow transplantation,
Mengjun Zhong, and Rili Gao, and Ruocong Zhao, and Youxue Huang, and Cunte Chen, and Kehan Li, and Xibao Yu, and Dingrui Nie, and Zheng Chen, and Xin Liu, and Zhuandi Liu, and Shaohua Chen, and Yuhong Lu, and Zhi Yu, and Liang Wang, and Peng Li, and Chengwu Zeng, and Yangqiu Li
August 2015, Experimental hematology,
Copied contents to your clipboard!